Protara Therapeutics, Inc.
TARA · XNASCIK 1359931fmd_0TJ0ZX8AY4VJAAP81KTSN7KCNSManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2012 to Sep 30, 2026, 56 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | – | – | – | – | – |
| Net interest income | – | – | – | – | (0) | – | – | – | – | – |
| Net investment income | – | – | – | – | – | – | 0 | – | – | – |
| Realized investment gains (losses) | – | – | – | – | – | – | 0 | 0 | – | 0 |
| Research and development | 19 | 22 | 12 | 4 | 12 | 21 | 17 | 25 | 32 | 43 |
| Total operating expenses | 29 | 30 | 21 | 8 | 34 | 47 | 67 | 44 | 49 | 65 |
| Operating income | (29) | (30) | (21) | (8) | (34) | (47) | (67) | (44) | (49) | (65) |
| Interest expense | – | – | – | – | 0 | 0 | – | – | – | – |
| Interest and investment income | – | – | – | – | 1 | 0 | 1 | 3 | 4 | 6 |
| Other non-operating income (expense) | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 3 | 5 | 7 |
| Income before taxes | (29) | (30) | (21) | (15) | – | – | – | – | 45 | 57 |
| Income tax expense | – | – | – | – | – | – | – | – | – | – |
| Net income from continuing operations | – | – | – | – | – | – | – | – | – | – |
| Net income | (29) | (30) | (21) | (8) | (34) | (47) | (66) | (40) | (45) | (57) |
| Net income to common shareholders | (29) | (37) | (21) | – | 34 | 47 | (66) | (40) | – | – |